{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:12:48Z","timestamp":1779909168457,"version":"3.53.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"crossref","award":["18987"],"award-info":[{"award-number":["18987"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NR-NET FP7 Marie Curie ITN"},{"name":"Italian Ministry of Health","award":["GR-2010-2314703"],"award-info":[{"award-number":["GR-2010-2314703"]}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.coph.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T06:39:58Z","timestamp":1536907198000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["The gut\u2013liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19"],"prefix":"10.1016","volume":"43","author":[{"given":"Marilidia","family":"Piglionica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Cariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.08.005_bib0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.coph.2018.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coph.2018.08.005_bib0015","doi-asserted-by":"crossref","first-page":"e005","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.coph.2018.08.005_bib0020","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1016\/j.febslet.2006.07.082","article-title":"Nuclear bile acid receptor FXR as pharmacological target: are we there yet?","volume":"580","author":"Modica","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.coph.2018.08.005_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-2275(20)41693-1","article-title":"Cholesterol 7 alpha-hydroxylase","volume":"18","author":"Myant","year":"1977","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2018.08.005_bib0030","doi-asserted-by":"crossref","first-page":"19375","DOI":"10.1016\/S0021-9258(17)32178-6","article-title":"Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase","volume":"269","author":"Falany","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.08.005_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00041433-199806000-00007","article-title":"New insights into bile acid transport","volume":"9","author":"Love","year":"1998","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.coph.2018.08.005_bib0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/hep.20627","article-title":"Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP\/ABCB11","volume":"41","author":"Hayashi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_bib0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1194\/jlr.M200394-JLR200","article-title":"Appearance of atypical 3 alpha,6 beta,7 beta,12 alpha-tetrahydroxy-5 beta-cholan-24-oic acid in spgp knockout mice","volume":"44","author":"Perwaiz","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2018.08.005_bib0050","doi-asserted-by":"crossref","first-page":"24784","DOI":"10.1074\/jbc.M111.329318","article-title":"Abcb11 deficiency induces cholestasis coupled to impaired beta-fatty acid oxidation in mice","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.08.005_bib0055","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.005_bib0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.21591","article-title":"Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4","volume":"46","author":"Morita","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_bib0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.005_bib0070","first-page":"1237","article-title":"Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis","volume":"145","author":"Mauad","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2018.08.005_bib0075","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.coph.2018.08.005_bib0080","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-2275(20)32022-8","article-title":"Subcellular organization of bile acid amidation in human liver: a key issue in regulating the biosynthesis of bile salts","volume":"41","author":"Solaas","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2018.08.005_bib0085","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1074\/jbc.M412752200","article-title":"The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter","volume":"280","author":"Dawson","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.08.005_bib0090","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1073\/pnas.91.11.4741","article-title":"Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol","volume":"91","author":"Gong","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2018.08.005_bib0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.physiol.64.082201.100300","article-title":"Bile salt transporters","volume":"64","author":"Meier","year":"2002","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.coph.2018.08.005_bib0100","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/hep.25929","article-title":"Emerging role of fibroblast growth factors 15\/19 and 21 as metabolic integrators in the liver","volume":"56","author":"Cicione","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_bib0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2018.08.005_bib0110","doi-asserted-by":"crossref","first-page":"27277","DOI":"10.1074\/jbc.M704244200","article-title":"Liver-specific activities of FGF19 require Klotho beta","volume":"282","author":"Lin","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.08.005_bib0115","doi-asserted-by":"crossref","first-page":"33304","DOI":"10.1074\/jbc.M803319200","article-title":"C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors","volume":"283","author":"Wu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2018.08.005_bib0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbalip.2014.08.005","article-title":"Tissue-specific actions of FXR in metabolism and cancer","volume":"1851","author":"Gadaleta","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coph.2018.08.005_bib0125","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.005_bib0130","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.coph.2018.08.005_bib0135","doi-asserted-by":"crossref","first-page":"e0149782","DOI":"10.1371\/journal.pone.0149782","article-title":"Hormesis in cholestatic liver disease; preconditioning with low bile acid concentrations protects against bile acid-induced toxicity","volume":"11","author":"Verhaag","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2018.08.005_bib0140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.coph.2018.08.005_bib0145","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2018.08.005_bib0150","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jhep.2012.06.016","article-title":"Deletion of IFNgamma enhances hepatocarcinogenesis in FXR knockout mice","volume":"57","author":"Meng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2018.08.005_bib0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.taap.2013.06.016","article-title":"Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice","volume":"272","author":"Li","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.coph.2018.08.005_bib0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2018.08.005_sbref0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hep.27274","article-title":"Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation","volume":"61","author":"Degirolamo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_sbref0170","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.08.005_bib0175","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2\u2212\/\u2212 (Abcb4\u2212\/\u2212) mouse cholangiopathy model by promoting biliary HCO(\u2212)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_sbref0180","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.1038\/s41598-017-11549-7","article-title":"Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(\u2212\/\u2212) mice","volume":"7","author":"Cariello","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2018.08.005_bib0185","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.coph.2018.08.005_bib0190","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nm.4363","article-title":"Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice","volume":"23","author":"Benoit","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2018.08.005_bib0195","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.22771","article-title":"High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis","volume":"49","author":"Schaap","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_bib0200","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2018.08.005_bib0205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.coph.2018.08.005_bib0210","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1158\/0008-5472.CAN-07-2325","article-title":"Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling","volume":"68","author":"Pai","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2018.08.005_bib0215","doi-asserted-by":"crossref","first-page":"e36713","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2018.08.005_sbref0220","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1038\/ncomms15433","article-title":"Non-cell-autonomous activation of IL-6\/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2018.08.005_bib0225","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2018.08.005_bib0230","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2018.08.005_sbref0235","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:01Z","timestamp":1761461401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":47,"alternative-id":["S1471489218300729"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.08.005","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gut\u2013liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}